Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
NCT03361228 · Incyte Corporation · PHASE1/PHASE2 · terminated · last registry update 2020-05-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated early based on emerging data with epacadostat and pembrolizumab.” | – | Registry record, Incyte Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IDO1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-22Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Dasatinib (NCT02750514)
- 2021-03-22Also stopped (terminated): Bristol-Myers Squibb, Nivolumab + Dasatinib (NCT02750514)
- 2021-02-26Also stopped (withdrawn): Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Pembrolizumab + Epacadostat (NCT03832673)
- 2020-12-29Results posted on the registry: Incyte Corporation, MEDI4736 + INCB024360 (NCT02318277)
- 2020-10-26Also stopped (withdrawn): Alain Algazi, Durvalumab + Epacadostat (NCT04231864)
- 2020-07-02Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nivolumab + Anti-GITR Monoclonal Antibody MK-4166 (NCT03707457)
- 2020-06-22Results posted on the registry: George Albert Fisher, Epacadostat + Pembrolizumab (NCT03196232)
- 2020-05-07Results posted on the registry: Incyte Corporation, Epacadostat + Pembrolizumab (NCT03085914)
- 2020-03-05Results posted on the registry: Incyte Corporation, Azacitidine + Pembrolizumab (NCT02959437)
- 2020-02-05Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03322540)
- 2020-02-05Also stopped (withdrawn): Dana-Farber Cancer Institute, Nivolumab + BMS-986205 (NCT04007588)
- 2020-01-29Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03322566)
- 2020-01-27Results posted on the registry: University of Chicago, Pembrolizumab + Epacadostat (NCT03463161)
- 2020-01-27Also stopped (terminated): University of Chicago, Pembrolizumab + Epacadostat (NCT03463161)
- 2019-12-20Also stopped (withdrawn): Incyte Corporation, Nivolumab + Epacadostat (NCT03342352)
- 2019-12-19Results posted on the registry: Incyte Corporation, MK-3475 + INCB024360 (NCT02178722)
- 2019-12-13Results posted on the registry: Georgetown University, Pembrolizumab + Epacadostat (NCT02364076)
- 2019-09-25Also stopped (terminated): Incyte Corporation, Itacitinib + Epacadostat (NCT02559492)
- 2019-09-10Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03358472)
- 2019-09-10Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03260894)
- 2019-08-29Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03361865)
- 2019-08-28Results posted on the registry: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03374488)
- 2019-06-13Results posted on the registry: Incyte Corporation, Nivolumab + Epacadostat (NCT03348904)
- 2019-06-13Also stopped (terminated): Incyte Corporation, Nivolumab + Epacadostat (NCT03348904)
- 2019-05-30Also stopped (withdrawn): M.D. Anderson Cancer Center, Epacadostat + Pembrolizumab (NCT03432676)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision